Views & Analysis Measuring the cost of diabetes Can patient education programmes start reducing the burden?
Views & Analysis The 'game changers' in diabetes: Novo and Lilly battle it ou... Two diabetes drugs, Lilly and Boehringer Ingelheim’s (BI) Jardiance and Novo Nordisk’s Victoza, have shown they can go beyond lowering blood sugar, and actually save lives and cut heart attacks
Views & Analysis Digital health round-up: a new dawn in diabetes care, and mo... A round-up of this week’s top digital healthcare news. Marco Ricci reports.
Views & Analysis The first ever ‘artificial pancreas’ is here - the iPhone of... Medtronic's hybrid closed loop device is the first step towards a true 'artificial pancreas'
News J&J's long-lasting diabetes combo approved in US Company looks to new drugs as US Remicade competition looms.
News Court sides with EU on decision to revoke Ocaliva's license Advanz Pharma's bid to keep its Ocaliva treatment for rare liver disease primary biliary cholangitis (PBC) on the EU market has ended in failure
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
